

卫生部规划教材  
全国高等医药院校教材

供药学类专业用

# 药 学 英 语

第二版

下册

胡廷熹 主编

人民卫生出版社

全国高等医药院校教材

供药学类专业用

# 药 学 英 语

第 二 版

下 册

胡 廷 熹 主 编

编者：(按姓氏笔画排列)

龙 葵 (华西医科大学)	胡廷熹 (中国药科大学)
张 立 (广东药学院)	郭莉萍 (北京医科大学)
李发美 (沈阳药科大学)	郭整风 (中国药科大学)
杜 辉 (中国药科大学)	裴元英 (上海医科大学)
杨树隼 (第二军医大学)	

人 民 卫 生 出 版 社

### 图书在版编目 (CIP) 数据

药学英语. 下册/胡廷熹主编. -2版. -北京:

人民卫生出版社, 2000

ISBN 7-117-03560-9

I. 药… II. 胡… III. 药理学-英语 IV. H31

中国版本图书馆 CIP 数据核字 (2000) 第 14109 号

## 药 学 英 语

第 二 版

下 册

主 编: 胡 廷 熹

出版发行: 人民卫生出版社 (中继线 67616688)

地 址: (100078) 北京市丰台区方庄芳群园 3 区 3 号楼

网 址: <http://www.pmph.com>

E-mail: [pmph@pmph.com](mailto:pmph@pmph.com)

印 刷: 北京市卫顺印刷厂

经 销: 新华书店

开 本: 787×1092 1/16 印张: 21.5

字 数: 452 千字

版 次: 1987 年 10 月第 1 版 2003 年 9 月第 2 版第 11 次印刷

标准书号: ISBN 7-117-03560-9/R·3561

定 价: 20.50 元

著作权所有, 请勿擅自用本书制作各类出版物, 违者必究

(凡属质量问题请与本社发行部联系退换)

## 全国高等医药院校药学专业 第四轮规划教材修订说明

为适应我国高等药学教育的改革和发展，在总结前三轮药学专业教材编写经验的基础上，卫生部教材办公室于1996年9月决定进行第四轮教材修订，根据药学专业的培养目标，确定了第四轮教材品种和修订的指导思想，药学本科教育的培养对象是从事一般药物制剂、鉴定及临床合理用药等工作的药师，教材修订应紧紧围绕培养目标，突出各学科的基本理论、基本知识，同时又反映学科的新进展。该套教材可供药学及相关专业选用。全套教材共22种，均经卫生部聘任的全国药学专业教材评审委员会审定。教材目录如下：

- |                  |        |                 |        |
|------------------|--------|-----------------|--------|
| 1. 高等数学（第三版）     | 毛宗秀 主编 | 11. 药理学（第四版）    | 李 端 主编 |
| 2. 医药数理统计方法（第三版） | 刘定远 主编 | 12. 药物分析（第四版）   | 刘文英 主编 |
| 3. 物理学（第三版）      | 王鸿儒 主编 | 13. 药用植物学（第三版）  | 郑汉臣 主编 |
| 4. 物理化学（第四版）     | 侯新朴 主编 | 14. 生药学（第三版）    | 郑俊华 主编 |
| 5. 无机化学（第三版）     | 许善锦 主编 | 15. 药物化学（第四版）   | 郑 虎 主编 |
| 6. 分析化学（第四版）     | 孙毓庆 主编 | 16. 药剂学（第四版）    | 毕殿洲 主编 |
| 7. 有机化学（第四版）     | 倪沛洲 主编 | 17. 天然药物化学（第三版） | 姚新生 主编 |
| 8. 人体解剖生理学（第四版）  | 龚茜玲 主编 | 18. 中医学基础（第四版）  | 李向中 主编 |
| 9. 微生物学与免疫学（第四版） | 李明远 主编 | 19. 药事管理学（第二版）  | 吴 蓬 主编 |
| 10. 生物化学（第四版）    | 吴梧桐 主编 | 20. 生物药剂学与药物动力学 | 梁文权 主编 |
|                  |        | 21. 分子生物学基础     | 史济平 主编 |
|                  |        | 22. 药学英语（第二版）   | 胡廷熹 主编 |

以上教材均由人民卫生出版社出版。

卫生部教材办公室

## 全国药学专业教材第二届评审委员会

主任委员：彭 司 勋

副主任委员：郑 虎

委员（以姓氏笔画为序）

王 夔 安登魁 李万亥 邹立家

郑俊华 胡昌奇 姚新生 梁文权

秘 书：翁玲玲 冉 兰

## 前 言

《药学英语》是在药学院系学生一、二年级英语教材基础上的药学专业英语教材。本套教材旨在培养学生阅读有关英语专业材料的能力，掌握必要的词汇，为专业内容的语言交流（口语和写作）打下坚实的基础。教材包括基础部分五十课课文及有关阅读材料五十篇。题材专业内容新颖，语言地道，学生易于吸收。每课中有词汇注解、课文注解和习题。教材还包括各专业（药物化学、药剂学、药理学、药物分析、生药学、生物化学和植物化学）的专业词汇及各类型专业文章，均取自国外近年的药学书刊和杂志。教科书最后部分为附录：（1）药学英语写作技巧；（2）总词汇表。本书分两册出版，上册内容为基础药学英语，下册内容为专业药学英语。

参加编写的有北京医科大学、上海医科大学、广东药学院、沈阳药科大学、华西医科大学、第二军医大学及中国药科大学的有关教授们。另外，特别聘请中国药科大学药学英语教师张宇辉同志为本教材秘书。

为了提高专业部分编写质量，特邀请中国药科大学赵守训教授（植物化学）、吴梧桐教授（生物化学）、李谦老师（生物化学）、刘国卿教授（药理学）、徐珞珊教授（生药学）、吉民副教授（药物化学）审查词汇和专业文章。本文特别重视校对工作，为最大限度地消除拼写错误，专门成立了校对小组。参加小组工作的除担任本书秘书的张宇辉老师外，还有中国药科大学九六级英语药学专业的钟莎、马欣、金飞燕、王森、王磊、王湛、周洲、张峻颖、高涛、唐铁鑫、张苡、刘明、刘泉等同学。此外，编者之一北京医科大学的郭莉萍老师又对全书作了细致的总体校阅及语言润色。他们工作认真，一丝不苟，使本书编写工作按时完成。在此本人一并致以衷心的感谢！

由于主编水平所限。谬误之处在所难免，敬请读者指正。

胡廷熹

于中国药科大学

1999.10

## Table of Contents

1.1	药物化学词汇 (Special Terms for Medicinal Chemistry)	1
1.2	药物化学专业文章 (Special Articles for Medicinal Chemistry)	9
2.1	药剂学词汇 (Special Terms for Pharmaceutics)	39
2.2	药剂学专业文章 (Special Articles for Pharmaceutics)	46
3.1	药理学词汇 (Special Terms for Pharmacology)	74
3.2	药理学专业文章 (Special Articles for Pharmacology)	82
4.1	药物分析词汇 (Special Terms for Pharmaceutical Analysis)	108
4.2	药物分析专业文章 (Special Articles for Pharmaceutical Analysis)	117
5.1	生药学词汇 (Special Terms for Pharmacognosy)	145
5.2	生药学专业文章 (Special Articles for Pharmacognosy)	153
6.1	生物化学词汇 (Special Terms for Biochemistry)	182
6.2	生物化学专业文章 (Special Articles for Biochemistry)	191
7.1	植物化学词汇 (Special Terms for Phytochemistry)	222
7.2	植物化学专业文章 (Special Articles for Phytochemistry)	230
	附录 I (Appendix I) 药学英语写作技巧 (Writing Skills)	253
	附录 II (Appendix II) 总词汇表 (Glossary Index)	287

## 1.1 药物化学词汇

### Special Terms for Medicinal Chemistry

#### A

- acetamide derivative 乙酰胺衍生物  
acetate 乙酸盐  
acetic acid 醋酸  
acetone 丙酮  
acetylene 乙炔  
acetylpenicillamine 乙酰青霉胺  
acetylsalicylic acid 乙酰水杨酸  
acid-catalyzed ketal formation 酸催化缩酮结构  
acidic 酸性的  
acidification 酸化  
acquired immunodeficiency syndrome 获得性免疫缺陷综合征  
activation 活化, 激化  
acylating 酰化  
adrenergic agent 肾上腺素能药  
adrenergic blocking agent 肾上腺素能阻断剂  
adverse reaction 副反应  
affinity 亲和力  
alcohol 乙醇  
aldehyde 醛  
alkane 链烷  
alkyl 烷基  
alkyl phenol 烷基酚  
alkylamine 烷基胺  
alkylaminoketone 烷基胺酮  
alkylating 烷化  
alkylsulfonamidophenethanolamine 烷基磺酰基苯乙基胺  
aluminum 铝  
amide 酰胺  
amidification in prodrug 前药中的酰胺化  
amidinopenicillanic acid 脒基青霉烷酸  
amino acid 氨基酸  
amino-3-indolepropionic acid 氨基-3-吲哚丙酸  
aminobenzoate 氨基苯甲酸酯  
amino-beta-hydroxybutyric acid 氨基-β-羟基丁酸  
amino-beta-hydroxypropionic acid 氨基-β-羟基丙酸  
amino-beta-mercaptopropionic acid 氨基-β-巯基丙酸  
aminocephalosporanic acid 氨基头孢烷酸  
aminoglutaramic acid 氨基戊酰胺酸  
aminopyrazines, diuretic 氨基吡嗪, 利尿剂  
aminosalicylic acid 氨基水杨酸  
aminosuccinic acid 天门冬氨酸  
aminothiadiazole 氨基噻二唑  
aminomethylbenzoic acid 氨基甲基苯甲酸  
amyl nitrite 亚硝酸异戊酯  
analgesic 止痛药  
analog 类似物

analog-prodrug hybrid 类似前药杂化  
anesthesia 麻醉  
anti-adiposity drug 抗肥胖症药  
anti-adrogen 抗雄激素  
anti-amebic agent 抗阿米巴药  
anti-anginal agent 抗绞痛药  
anti-anxiety agent 抗焦虑药  
anti-arrhythmic agent 抗心律失常药  
anti-arthritic agent 抗关节炎药  
anti-asthmatic drug 镇咳药  
antibacterial 抗细菌的  
antibiotics 抗生素  
anti-convulsant agent 抗惊厥药  
anti-depressant agent 抗抑郁药  
anti-diabetic agent 抗糖尿病药  
anti-diarrheal agent 抗腹泻药  
anti-dopaminergic drug 抗多巴胺能药  
anti-emetic agent 止吐药  
anti-epileptics 抗癫痫药  
anti-estrogen 抗雌激素  
anti-filarial drug 抗丝虫药  
antifungal 抗真菌的  
anti-helminthic drug 抗蠕虫药  
anti-hemophilic 抗血友病的  
anti-hemorrhoidal agent 抗痔药  
anti-histamine 抗组胺药  
anti-hypertensive agent 抗高血压药  
anti-inflammatory agent 抗炎药  
anti-inhibitor coagulant complex 抗抑  
制剂促凝剂复合物  
anti-leishmanial agent 抗利什曼虫药  
anti-leprosy agent 抗麻风药  
anti-lipemic agent 抗血脂药  
anti-malarial 抗疟药  
anti-metabolite 抗代谢药  
anti-migraine drug 抗偏头痛药  
anti-protozoal agent 抗原生动动物药

anti-psychotic 抗精神病药  
anti-oxidant 抗氧化剂  
antipyretic 退热药  
anti-rheumatics 抗风湿药  
anti-schistosomal drug 抗血吸虫药  
antiseptics 防腐剂  
anti-spasmodic agent 解痉药  
anti-thrombotics 抗血栓形成药  
anti-thyroid agent 抗甲状腺药  
anti-trematodes 抗吸虫药  
anti-trichomonal 抗毛滴虫药  
anti-tuberculous agent 抗结核药  
anti-tussive 镇咳药  
anti-ulcer agent 抗溃疡药  
anti-varicose drug 抗静脉曲张药  
antiviral agent 抗病毒药  
arylacetic acid derivative 芳基乙酸衍  
生物  
arylalkylamine 芳基烷胺  
ascorbic acid 抗坏血酸  
ascorbyl palmitate 抗坏血酸棕榈酸酯

## B

$\beta$ -lactamase  $\beta$ -内酰胺酶  
basic 碱性的  
benzimidazole 苯并咪唑  
benzaldehyde 苯甲醛  
benzodiazepine 苯并二氮  
benzofuran 苯并呋喃  
benzoic acid 苯甲酸  
benzophenone 二苯酮  
benzoylperoxide 过氧化苯甲酰  
benzquinamide 苯喹胺(止吐药)  
bichloroacetic acid 二氯乙酸  
bicyclic compound 二环化合物  
biphenylacetic acid 联苯乙酸  
 $\beta$ -lactam antibiotics  $\beta$ -内酰胺抗生素



bulky group 空间障碍基团  
bond-covalent 共价键  
bond-dipole 偶极键  
bond-hydrogen 氢键  
bond-ion-dipole 离子偶极键  
bond-ionic 离子键  
bretylium tosylate 溴苯铵(降压药)  
broad-spectrum antibacterial agent 广  
谱抗菌剂  
bromide 溴化物  
buffer 缓冲剂  
butoxyethyl nicotinate 烟酸丁氧乙基酯

### C

carbohydrate metabolism drug 碳水化  
合物代谢药  
carbutamide 磺胺丁脒(低血糖)  
cardiac glycoside 强心甙  
cardiovascular agent 心血管药  
cephalosporanic acid 头孢烷酸  
cephalosporin 头孢菌素  
channel blocker 通道阻断剂  
channel former 通道构象  
charge densities 电荷密度  
charge transfer 电荷转移  
chelating 螯合  
chelating agent 螯合剂  
chemical name 化学名  
chemical structure 化学结构  
chemoreceptor trigger zone 化合受体  
触发区域  
chemotherapeutic 化疗的  
chiral center 手性中心  
chloramphenicol 氯霉素  
chloride 氯化物  
cholinomimetic 拟胆碱作用的  
chromic chloride 氯化铬

complementarity between drug and re-  
ceptor 药物受体之间互补  
compound 化合物  
computer assisted drug design 计算机  
辅助药物设计  
configuration 构型  
conformation 构象  
congener 同族元素  
conjugation 共轭  
conjugative effect 共轭效应  
constant values of substituent 取代基  
常数值  
cooperative effect 协同效应  
coumarin 香豆素  
cyclohexanone 环己酮  
cyclophosphamide 环磷酰胺(抗肿瘤)

### D

dealkylation 去烷基化  
deamination 脱氨基  
dehalogenation 去卤化  
dehydroacetic acid 脱氢乙酸  
Development of adrenocorticoid drugs  
类肾上腺皮质激素药物的进展  
dichlorotetrafluoroethane 二氢四氟乙  
烷  
diphenylpropylamines and isosteres 二  
苯基丙胺及异构体  
disulfide 二硫化物  
diuretic 利尿剂  
dopamine 多巴胺  
double esters 二酯  
drug-parasite-host relationship 药物、  
寄生虫和宿主间关系

### E

electron charge distribution 电子电荷

的分布

electronic affinity 电子亲和力  
electronic charge density 电荷密度  
electronic distribution 电子分布  
electronic polarizability 电极化  
electronic states 电状态  
electrophilic 亲电性  
empirical electronic parameter 经验电  
参数  
endogenous substance 内源性物质  
epimerization 差向异构化  
epinephrine 肾上腺素  
epoxide 环氧化合物  
esterification 酯化  
estradiol 雌二醇  
ether 醚  
ethyl 乙基  
ethylenediamine 乙二胺

### F

fluoroacetamide 氟乙酰胺  
food additive 食物添加剂  
formaldehyde 甲醛  
formate 甲酸盐  
free valence 游离价  
frontier electron density 前沿电荷密度

### G

gases 气体  
general structure 一般结构  
glucose 葡萄糖  
glycinate 甘氨酸盐  
glycoside 糖苷  
group 基团

### H

haloacetamide 乙酰胺盐

halogen 卤素

halogenation 卤化  
hammett's constant Hamme 比常数  
Hansch's equation 汉施方程  
hair growth stimulant 毛发生长刺激  
heteroarylacetic acid 杂环芳基乙酸  
heterocyclic compound 杂环化合物  
heterocyclic isosteres 杂环异构体  
highest occupied molecular 最高占有  
分子  
histamine 组胺  
HOMO (highest occupied molecular or-  
bital) 最高能量占有轨道  
Hueckel molecular orbital Hucked 分  
子轨道

hybrid 杂化物

hybrid substances 杂化物

hybridization 杂交

hydrazino 胼基

hydrochloric acid 盐酸

hydrochlorothiazide 氢氯噻嗪

hydroiodic acid 氢碘酸

hydrophilia 亲水性

hydrophobic interaction 疏水作用

hydrophobicity constant 疏水性常数

hydroxide 氢氧化合物

hydroxy (前缀)羟基

hydroxyl group 羟基

hydroxylamine 羟胺

hydroxylation 羟基化

hydroxypropyl 羟基丙基

hydroxyurea 羟基脲

hypochlorites 次氯酸盐

### I

imidazole 咪唑

imidazoline 咪唑啉

immunomodulator 免疫调节剂  
immunostimulant drug 免疫刺激剂  
indolealkaloid alkaloid 吲哚烷胺生物碱  
insecticide 杀虫剂  
interatomic distance 原子间距  
intrinsic activity 内在活性  
isobutyric acid 异丁酸  
iodine 碘  
ion-exchange resin 离子交换树脂  
ionization 离子化  
iron 铁  
isobutyltriphenyl butylamine 异丁基三苯基丁胺  
isomer 异构体  
isoprofen 异布洛芬  
isosteres 异构体  
isosterism 异构化

## J

journals on medicinal chemistry 药物化学杂志

## L

latentiation 潜伏化  
lead optimization 先导优化  
linear free-energy model 线性自由能模型  
lipid solubility of absorption 吸收的脂溶性  
liposolubility 脂溶性  
lowest empty molecular orbital 最低能量空轨道

## M

macrolide antibiotics 大环内酯抗生素  
macromolecular 大分子

Mannich 曼尼期(人名)  
mechanism of action 作用机制  
mercaptapurine 巯基嘌呤  
metal 金属  
methyl 甲基  
methylchromone 甲基色酮  
methyldopa 甲基多巴  
methylhexaneamine 甲基己胺  
modeling 模拟  
models of action 作用模型  
molar 摩尔  
molecular modification 分子修饰  
muscarine 蕈毒碱  
muscle relaxant 肌松剂  
mutual prodrug 协同前药

## N

nasal decongestant 鼻减充血剂  
nervous system 神经系统  
net electronic charge 净电荷  
nicotinamide 烟酰胺  
nicotinate 烟酸酯(盐)  
nitrate ester 硝酸酯  
nitric acid 硝酸  
nitriles 腈  
nitro- 硝基  
nitrogen 氮气  
nitrogen mustard 氮芥  
nitroheterocyclic derivatives 硝基杂环衍生物  
nitrous oxide 氧化亚氮  
nitrobenzamides 硝基苯甲酰胺  
nondepolarizing 非去极化  
non-specific drug 非特性药  
non-steroidal anti-inflammatory agent 非甾体抗炎药  
nuclear magnetic resonance 核磁共振

## O

occupancy theory 占有理论  
 octanoic acid 辛酸  
 optimization 优化  
 organic iodine 有机碘  
 organometallic compound 有机金属化合物  
 organophosphates 有机磷酸盐  
 oxidation 氧化  
 oxide 氧化物  
 oxide formation 氧化物生成  
 oxidizing agent 氧化剂  
 oxygen 氧

## P

palmitate 棕榈酸酯(盐)  
 paraformaldehyde 多聚甲醛  
 parameter 参数  
 partition coefficient 分配系数  
 penicillamine 青霉胺  
 penicillin 青霉素  
 perchlorate 高氯酸盐  
 permanganate 高锰酸盐  
 peroxide 过氧化物  
 pharmaceutical 制药的  
 pharmacology 药物化学  
 pharmacophore 药效基团  
 pharmacophoric moieties 药效团的部  
 分  
 phenol 苯酚  
 phenothiazine 吩噻嗪  
 phenylacetic acid 苯乙酸  
 phenylalkylamine 苯烷胺  
 phenylbutyric acid 苯基丁酸  
 phenylethyl alcohol 苯乙醇  
 phosphate 磷酸盐(酯)

phosphoric acid 磷酸  
 phosphorylating agent 磷酸化剂  
 physicochemical properties 物化性质  
 physiological 生理的  
 piperazine 哌嗪  
 piperazinedione 哌嗪二酮  
 piperidione 哌啶二酮  
 polarizability 极化  
 polyethylene 聚乙烯  
 polymer 多聚体  
 polystyrene sulfonate 硫酸聚苯乙烯  
 polyvinyl 聚乙烯  
 potassium 钾  
 prodrug 前药  
 propanediol 丙二醇  
 propionic acid 丙酸  
 psychoactive agent 对精神起显著作用  
 药  
 pump 泵  
 purified 纯净的  
 pyrazinamide 吡嗪酰胺

## Q

QSAR 定量构效关系  
 quaternary ammonium 季胺  
 quinazoline 喹唑啉  
 quinidine 奎尼丁  
 quinolone 喹诺酮

## R

random screening in drug discovery 药  
 物发现的随机筛选  
 rare earth metal salts 稀有土金属  
 rational approach in drug design 合理  
 药物门  
 rational design 合理设计  
 receptor 受体

reversible 可逆的  
ring closing or opening 闭环或开环

### S

salicyl alcohol 水杨醇  
salicylate 水杨酸盐  
salicylic acid 水杨酸  
salt 盐  
selenium sulfide 硫化硒  
semi-synthetic 半合成的  
silica gel 硅胶  
silicon compound 硅化物  
silicon dioxide 二氧化硅  
silver nitrate 硝酸银  
simplification 简化  
slow channel 慢道  
smooth muscle 平滑肌  
soft drugs 软药  
solubilizing agent 增溶剂  
solvent 溶剂  
sorbic acid 山梨酸  
specificity 特异性  
spectrum of activity 作用谱(作用范围)  
stability 稳定性  
stereochemical 立体化学的  
steric 空间(排列)的  
steric constant 立体参数  
stereochemistry of acetylcholine 乙酰胆碱立体化学  
steroid 甾体  
streptomycin 链霉素  
structure-activity relationship 构效关系  
sublimed sulfur 升华硫  
succinylcholme 琥珀酰胆碱  
succinonitrile 琥珀腈

sulfide 硫化物  
sulfonamides 磺酰胺类  
sulfone 砒  
sulfonic acid 磺酸  
sulfonylureas 磺酰脲类  
sulfur 硫  
sunscreen 防晒  
surfactant 表面活性剂  
synthesis 合成

### T

tartaric acid 酒石酸  
tetracyclines 四环类  
thermodynamic activity 热力学活性  
thienamycin 硫霉素  
thiol 巯基  
topical 表面的  
trichloroethylene 三氯乙烯  
tricyclic 三环的  
triphenylmethane 三苯甲烷

### U

unsaturated 不饱和  
urea 脲

### V

vapor pressure 蒸气压  
vasodilator 血管扩张剂  
vinylpyrimidine 丁吡

### W

water for injection 注射用水  
water for irrigation 冲洗用水  
white lotion 白色洗液  
white ointment 白色软膏

**X**

X-ray diffraction X线衍射  
xylose 木糖

**Z**

zinc 锌

**Y**

yellow ferric oxide 黄色氧化铁

## 1.2 药物化学专业文章

### •Special Articles for Medicinal Chemistry

#### Text One

#### Some Aspects of Medicinal Chemistry Today

##### I . THE SCIENTIFIC ASPECT

The term "drug" describes biologically active molecules such as xenobiotics<sup>1</sup> (foreign or exogenous chemicals used therapeutically against human, animal, and plant diseases), metabolic inhibitors, pesticides and insecticides, or even physiologically acting compounds (such as endorphins<sup>2</sup>, plant poisons, snake venoms<sup>3</sup>). They induce many more or less interdependent biological actions. Generally speaking, the chemical properties of compounds and, hence, the structures determine the mechanism of biological actions. When dealing with thousands of drugs, it becomes necessary to organize the large body of structure-activity relationships (SARs). In 1975, the relationship between theoretical medicine (pharmacology, toxicology, biochemistry), physical chemistry, and *multidimensional* mathematics and statistics was called "pharmacochemistry". One goal of pharmacochemistry is to reduce data to a few quantitative structure-activity relationships (QSARs). This is the *intellectual* aspect of the probabilistic<sup>4</sup> QSAR game. A second goal is to develop an understanding of SARs: for instance, a mechanistic interpretation of molecular drug-receptor interactions. This is the *rational* aspect of the QSAR game and should not be overlooked. Third, QSAR also is a method to improve the probability of discovering novel drugs within a series of closely related compounds without an enormous capital outlay, to reduce synthesis cost, and to make a plan of research. This is the *commercial* aspect. Therefore, pharmacochemistry is a science in which a close connection exists between the interests of researchers in how chemicals influence nature and the technological achievement of their ideas. There is no other science where creativity of researchers may lead to so large an improvement in human health and food technology.

Needless to say, the *absence of QSARs* can only be due to the multiplicity<sup>5</sup> and

complexity of SARs as a whole, or deficient methods of investigation (experimental bioassay, physicochemical constants, statistical approaches).

The establishment of a mathematically oriented *unidimensional* QSAR is now in the last of four stages: enthusiasm, initial stabilization, disappointment, and final stabilization. The large body of successful QSARs has encouraged the drug designer to use unidimensional QSAR approaches that are now routine, and enthusiasm for mathematically oriented medicinal chemistry seems to be quite understandable. The practical success of such semitheoretical (or semiempirical) techniques should not be overlooked, because it is not yet possible to design drugs in a purely logical and theoretical fashion; each kind of QSAR could be regarded as "making the best of a bad job". An *ab initio* drug design is currently not feasible and will not become so in the near future, and the lion's share of spectacular and brandnew developments has become almost entirely from pharmacological screening tests. To a large degree, the research is still empirical, especially because of the lack of absolute ways to describe the molecules physicochemically. Further, drug action is highly complex in nature, and formal description of *multidimensional* processes is rather difficult to realize. Nevertheless, mathematical methods are becoming an increasingly vital link in developing safer chemicals. Based on multivariate QSARs, the *probability* of successfully developing less toxic but more potent congeners<sup>6</sup> of drugs increases. Therefore, it must borne in mind that QSAR is a game of probabilities. Perfect correlations between chemical structure and biological activity can never be expected and are not necessary to obtain insight into the tendency of SARs. Because of the probabilistic character, *outliers* also may be expected. These may often represent the existence of a particular effect that can provide large increases in biological activity. And outliers are more interesting, in general, than those members of a closely related series of compounds that are well recognized or fitted. Eventually, outliers can be included in a more global QSAR model by including additional physicochemical terms.

Before any QSAR can be made, it is quite clear that the parameters reflecting the complex behavior of drugs *in vitro* and in living animals must be determined experimentally. Therefore, the study of *biosystems* requires sufficient insight into the nature and limitations of biological starting material, too. It should be self-evident that equally high demands can be made on expressions of biological activity as on mathematical tools with which these data are processed, *since the results cannot be more reliable than this starting material* and the physicochemical terms.

Classical methods of *communications* depend on regularly covering a few periodicals or attending a few scientific meeting each year. These methods are no longer adequate to cope with the growing flood of scientific information. Only modern



information services and data-bank programs can help to solve the problem. Multivariate approaches in this field reflect a real progress and advantage because, for example, hierarchical<sup>7</sup> classification of information becomes possible. The type of information that is then needed is typed into the desk computer on a typewriter-like terminal, and title and abstracts are immediately printed at the terminal or displayed on a video screen. In addition to pharmacological-toxicological data banks, synthesis-route discovery programs using a reaction library and methods of artificial intelligence allow computer users to obtain information on, say, which of the compounds are relatively easy and which are difficult or impossible to synthesize. The intermediates of various synthesis routes are often biologically active and could be useful leads for new substances.

## II . THE MULTIDIMENSIONAL VIEW

It is now widely accepted that the multidimensional view of data analysis can serve as a useful tool in solving problems in medicinal chemistry, although *there seems to be little consensus on what type of approach is the most appropriate. And in specific applications to drug design, there may be considerable debate on whether a particular procedure is the adequate one.* It is not within the scope of this book to argue the pros and cons; the goals here are to give the theoretical assumptions made by mathematicians in the process of deriving the theoretical “backbone” of multivariate techniques; to describe, in terms as nonmathematical as possible, a set of such methods having value from the (subjective) author’s standpoint; and to illustrate the different designs by numerical examples. After presenting a multivariate view, I leave it to the reader to decide on a preferred approach. It should also be emphasized that during the years since the first publications of multivariate methods in the late 1920s, considerable progress has taken place in multidimensional methodology. Obviously, not all the developments can be described, and some must be excluded, such as factor analysis; *we mainly focus our attention on techniques that are based on the general linear multivariate hypothesis.* According to Popper, we also do not strictly distinguish between theory and practical application.

Among many other indications, one expression of the multidimensional nature of drug action is its dependence on biorhythmic phenomena. For example, when the drug concentration in plasma must be maintained at a minimal effective level, an oscillatory<sup>8</sup> multicompartiment biosystem with inputs, outputs, and constraints must be considered, including controllability, observability, and system stability criteria. The experimental analysis is rather difficult, but such questions can be resolved only through multidimensional approaches.